Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
(4) - EconoTimes)
CAMBRIDGE, Mass., March 31, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, granted equity awards on March 31, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to four individuals hired by Sarepta in March 2017. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 16,920 shares of Sarepta's common stock. The options have an exercise price of $29.60 per share, which is equal to the closing price of Sarepta's common stock on March 31, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit us at www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
